Ambicion

AMBICION Co., Ltd.

MENU

News

Acquisition of The New Patent “Technology for Efficient Activation of NKT Calls”

January 15, 2019

AMBICION Co., Ltd announced that RIKEN and AMBICION acquired the new patent “Technology for Efficient Activation of NKT Calls” in Japan.
This patent acquisition enforces the exclusivity of its business regarding the Natural Killer T (NKT) cell-targeted cancer therapy. Patent No 447947 Dat...

AMBICION participates in Regenerative Medicine JAPAN 2018

September 12, 2018

AMBICION participates in Regenerative Medicine JAPAN 2018 (held with Bio Japan 2018) as an exhibitor on October 10 to 12. (Booth number: R-22)
We’re looking forward to seeing you at our booth. For more information
Regenerative Medicine JAPAN 2018 ...

Ghent University and AMBICION Entered into a Patent Assignment Agreement on the US rights to the Galacto-pyranosyl compounds.

May 31, 2018

Ghent University (Ghent, Belgium) and AMBICION (Tokyo, Japan) announced that they entered into a patent assignment agreement on the US rights to the Galacto-pyranosyl compounds as developed by the groups of Prof. Serge Van Calnebergh and Prof. Dirk Elewaut.
According to the agreement, AMBICIO...
1 2